Carilizumab and Apatinib

DRUG2 trials

Sponsors

Peking University Third Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Conditions

Gastric CancerMucosal Melanoma

Phase 2

PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer

RecruitingNCT06792162

Peking University Third HospitalGastric Cancer

Start: 2023-04-20End: 2027-04-30Target: 20Updated: 2025-01-24

Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma

Not yet recruitingNCT07236528

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolMucosal Melanoma

Start: 2025-11-30End: 2028-05-31Target: 30Updated: 2025-11-19